U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07019337) titled 'Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer' on June 05.
Brief Summary: This is a prospective, open-label, multi-cohort, phase II study to evaluate the efficacy and safety of Oral metronomic capecitabine combined with pyrotinib in patients with HER2-positive advanced breast cancer who had received prior anti-HER2 ADC drugs (including T-DXd, SHR-A1811, T-DM1, etc.) before treatment.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
HER2-positive Breast Cancer
Metastatic Breast Cancer
Intervention:
DRUG: Pyrotinib
400mg or 320mg qd
DRUG: Capecitabine...